

Viewpoint

Value-Based Pricing for Drugs Theme and Variations

Anna Kaltenboeck, MA¹; Peter B. Bach, MD²

» [Author Affiliations](#)



JAMA

Published Online: June 5, 2018

2018;319;(21):2165-2166.

doi:10.1001/jama.2018.4871



In December 2017, the US Food and Drug Administration approved voretigene neparvovec-rzyl (Luxturna), a one-time genetic treatment manufactured by Spark Therapeutics that must be injected into the eye and can improve the vision of individuals with biallelic *RPE65* mutation-associated retinal dystrophy, a rare genetic condition that affects approximately 1000 to 2000 people in the United States each year. The therapy was priced \$850 000 per treatment, just below the million dollar threshold some had anticipated.

[Get Access](#)

[View Full Text](#) | [Download PDF](#)